Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 11
Submit an article Journal homepage
4,092
Views
16
CrossRef citations to date
0
Altmetric
Oncology

Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective

Boon Piang Chera Agency for Care Effectiveness, Ministry of Health, Singapore, SingaporeORCID Iconhttps://orcid.org/0000-0001-5745-8133
ORCID Icon,
Kar Yee Gana Agency for Care Effectiveness, Ministry of Health, Singapore, SingaporeORCID Iconhttps://orcid.org/0000-0002-2406-2025
ORCID Icon,
Mohamed Ismail Abdul Aziza Agency for Care Effectiveness, Ministry of Health, Singapore, SingaporeORCID Iconhttps://orcid.org/0000-0003-3606-7672
ORCID Icon,
Liang Lina Agency for Care Effectiveness, Ministry of Health, Singapore, Singapore
,
William Ying Khee Hwangb National Cancer Centre Singapore, Singapore, Singapore;c Department of Haematology, Singapore General Hospital, Singapore, Singapore;d Duke-NUS Medical School, Singapore, SingaporeORCID Iconhttps://orcid.org/0000-0003-0143-6263
ORCID Icon,
Li Mei Poone Department of Haematology-Oncology, National University Hospital Singapore, Singapore, SingaporeORCID Iconhttps://orcid.org/0000-0002-8854-9414
ORCID Icon &
Kwong Nga Agency for Care Effectiveness, Ministry of Health, Singapore, SingaporeCorrespondence[email protected]
 show all
Pages 1321-1329 | Received 23 Jun 2020, Accepted 06 Aug 2020, Published online: 25 Aug 2020

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Niamh Carey, Joy Leahy, Lea Trela-Larsen, Laura Mc Cullagh & Michael Barry. (2023) Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting. Journal of Market Access & Health Policy 11:1.
Read now
Weijia Wu, Shuyi Ding, Zhang Mingming, Zhou Yuping, Xueshan Sun, Zixuan Zhao, Yi Yang, Yongxian Hu & Hengjin Dong. (2023) Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China. Journal of Medical Economics 26:1, pages 701-709.
Read now
Panagiotis Petrou. (2023) Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update. Expert Review of Pharmacoeconomics & Outcomes Research 23:6, pages 625-650.
Read now
Mondher Toumi, Omar Dabbous, Samuel Aballéa, Michael F. Drummond, Johann-Matthias Graf von der Schulenburg, Daniel C. Malone, Peter J. Neumann, Sean D. Sullivan & Sean Tunis. (2023) Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal. Expert Review of Pharmacoeconomics & Outcomes Research 23:5, pages 483-497.
Read now
Xiao Jun Wang, Yi-Ho Wang, Shing Chau Tony Li, Christina Gkitzia, Soon Thye Lim, Liang Piu Koh, Francesca Lorraine Wei Inng Lim & William Ying Khee Hwang. (2021) Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore’s private insurance payer’s perspective. Journal of Medical Economics 24:1, pages 637-653.
Read now

Articles from other publishers (11)

Weijia Wu, Yuping Zhou, Yannan Wang, Syed Afroz Keramat, Namal N. Balasooriya, Zixuan Zhao, Yi Yang, Tracy Comans & Hengjin Dong. (2023) Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis. Applied Health Economics and Health Policy 21:5, pages 773-783.
Crossref
Sean P. Gavan, Stuart J. Wright, Fiona Thistlethwaite & Katherine Payne. (2023) Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review. PharmacoEconomics 41:6, pages 675-692.
Crossref
Christopher Parker, Fei Fei Liu, Kristen A. Deger, Conrado Franco-Villalobos, Irina Proskorovsky, Scott J. Keating & Sonja Sorensen. (2023) Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States. Advances in Therapy 40:5, pages 2355-2374.
Crossref
Christopher Hillis, Colin Vicente & Graeme Ball. (2022) The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada. PharmacoEconomics 40:9, pages 917-928.
Crossref
Francesca Lorraine Wei Inng Lim, Chen Yunxin, Feng‐Ju Huang & William Ying Khee Hwang. (2022) A unique hub‐and‐spoke model to optimize patient management in lymphoma using novel CAR‐T cell therapy in Southeast and South Asia. Hematological Oncology 40:S1, pages 4-12.
Crossref
Francesca Lorraine Wei Inng Lim, Chen Yunxin, Feng‐Ju Huang & William Ying Khee Hwang. (2022) A unique hub‐and‐spoke model to optimize patient management in lymphoma using novel chimeric antigen receptor‐T cell therapy in Southeast and South Asia. Hematological Oncology.
Crossref
Zhi-Fan Li & Na-Qiong Wu. (2022) The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy. Frontiers in Genetics 13.
Crossref
Steven Simoens, Katrien De Groote & Cornelis Boersma. (2022) Critical Reflections on Reimbursement and Access of Advanced Therapies. Frontiers in Pharmacology 13.
Crossref
Joseph Khoa Ho, Kennedy Borle, Nick Dragojlovic, Manrubby Dhillon, Vanessa Kitchin, Nicola Kopac, Colin Ross & Larry D. Lynd. (2021) Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review. PharmacoEconomics 39:9, pages 995-1019.
Crossref
Benedetto Bruno, Ralph Wäsch, Monika Engelhardt, Francesca Gay, Luisa Giaccone, Mattia D’Agostino, Luis-Gerardo Rodríguez-Lobato, Sophia Danhof, Nico Gagelmann, Nicolaus Kröger, Rakesh Popat, Niels W.C.J. Van de Donk, Evangelos Terpos, Meletios A. Dimopoulos, Pieter Sonneveld, Hermann Einsele & Mario Boccadoro. (2021) European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. Haematologica 106:8, pages 2054-2065.
Crossref
Athena HY Chew, Nagarajan Chandramouli, Ravindran Kanesvaran, Gopalakrishna N Iyer & William YK Hwang. (2020) Winning the Fight Against Cancer. Annals of the Academy of Medicine, Singapore 49:10, pages 779-788.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.